Gilead Sciences Pty Ltd

Gilead’s mission is to advance patient care by developing therapeutics to treat life-threatening diseases. We apply biopharmaceutical science to create medicines to treat conditions including Haematology/Oncology (ZYDELIG®   [idelalisib]),  HIV (DESCOVY® [emtricitabine/tenofovir alafenamide], GENVOYA® [elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide], STRIBILD® [tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat], EVIPLERA® [tenofovir disoproxil fumarate & emtricitabine & rilpivirine], ATRIPLA®  [tenofovir disoproxil fumarate & emtricitabine & efavirenz],  TRUVADA® [emtricitabine & tenofovir disoproxil fumarate], EMTRIVA® [emtricitabine], VIREAD® [tenofovir disoproxil fumarate]), chronic hepatitis B (VIREAD® [tenofovir disoproxil fumarate], HEPSERA® [adefovir dipivoxil]), chronic hepatitis C (EPCLUSA® [sofosbovir/velpatasvir], HARVONI® [ledipasvir & sofosbovir], SOVALDI® [sofosbuvir]), and systemic fungal infections (AmBisome® [liposomal amphotericin B])

Company name: Gilead Sciences Pty Ltd
Address: Level 6, 417 St Kilda Road, Melbourne, Victoria, 3004, Australia
Phone: +61 (0)3 9272 4400
Freecall: 1800 806 112
Fax:  +61 (0)3 9272 4411 

Website: http://www.gilead.com/about/worldwide-operations/australia

 

  Stand/Booth No. 36